- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Discusses Management of Pediatric Type 1, 2 Diabetes
Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, discusses some of the challenges of treating pediatric patients with type 1 or type 2 diabetes.
The American Diabetes Association (ADA) recognizes that type 2 diabetes in young people is a more severe disease, said Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the ADA.
Transcript
Section 14 of the ADA's 2022 Standards of Medical Care in Diabetes added new information about pediatric type 1 and type 2 diabetes. What is lacking in the care for children?
We recognize that particularly type 2 diabetes in young people is a more severe disease. It progresses more rapidly, and the risk of complications is higher. It's, in essence, a more aggressive disease, and so it's important that clinicians think about how to best manage those individuals and also to screen for them.
Young people with type 1 diabetes continue to be a challenging group and particularly young adults where, if anything, A1C [glycated hemoglobin], not only has it not gotten any better for that population, but it has gotten worse despite all of the technology that's become available. So it was important for us to emphasize the best management about type 1 and type 2 diabetes in children.
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
